Showing 811-820 of 3104 results for "".
COVID-19 Impact: Interrupted EBD Regimens
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/covid-19-impact-on-interrupted-ebd-regimens/19764/Aesthetic treatments aren't considered essential at this time, but what do you do about patients who were in the middle of a series of energy-based treatments? Eric Bernstein, MD says the good news is that the skin doesn't forget. Now is a great time to focus on topical therapies that complement in-Six Tools to Build Retirement Wealth
https://practicaldermatology.com/topics/practice-management/six-tools-to-build-retirement-wealth/23189/A review of retirement planning tools for doctors and an outline of the rules that govern their use.Almirall/Allergan, LEO/Bayer Deals
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-almirall-allergan-leo-bayer-deals/18240/Leo Pharma has agreed to acquire Bayer's global prescription dermatology unit, and Almirall will acquire Allergan's US portfolio of medical dermatology drugs. When it comes to patient engagement, aesthetic practices often have the right mindset, but they may lack the skills or time necessary to execNew Therapeutic Options for the Treatment of Psoriatic Arthritis: IL-17 Blockers
https://practicaldermatology.com/topics/psoriasis/new-therapeutic-options-for-the-treatment-of-psoriatic-arthritis-il-17-blockers/20447/Are TNF inhibitors still the gold standard for PsA?Valeant's Plan for Derm; VCS Highlights
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-valeant-s-plan-for-derm-vcs-highlights/18587/Amid reports that its Obagi and Solta units may be sold off, Valeant Pharmaceuticals is assuring investors that the company is focused on the future and has plans to fix its dermatology unit. Vegas Cosmetic Surgery has wrapped up its 12th program, gathering dermatologists, plastic surgeons, facial pFDA Warns on Expression; Lilly's Ixekizumab Data Promising
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-warns-on-expression-lilly-s-ixekizumab-data-promising/19093/Lilly's Ixekizumab phase III data look good for psoriasis, and the FDA warns on improper use of Expression hyaluronic acid as a dermal filler. Plus, Sitavig is available for herpes labialis, and Syneron's laser gets an onychomycosis clearance.The Safety of New Systemics
https://practicaldermatology.com/issues/practicaldermatology-com-march-2025/the-safety-of-new-systemics/33159/Practical Dermatology Chief Medical Editor Neal Bhatia, MD, FAAD, provides an overview of the safey of systemic therapies such as JAK inhibitors and other similar drugs, giving dermatologists a high-level look at what they need to help clinical decision-making.Nitric Oxide-Releasing Cleanser for Plantar Warts
https://practicaldermatology.com/topics/clinical-case-reports/nitric-oxide-releasing-cleanser-plantar-warts/27121/The authors present a case study of a 12-year-old girl developed a few small warts on the plantar surface of both feet, and over a 6-month period.Unlocking the Potential of Regenerative Medicine in Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/unlocking-the-potential-of-regenerative-medicine-in-dermatology/24022/Advances in regenerative medicine have led to a new generation of therapeutic approaches and options.How Exceptional Reception Design Can Maximize Sales
https://practicaldermatology.com/topics/practice-management/how-exceptional-reception-design-can-maximize-sales/23779/Many factors determine the impact of this generally small but important space.